Abstract: The invention relates to a fusion protein comprising glucose-6-phosphatase 2 protein and a polypeptide derived from avian or mammalian Orthoreovirus muNS protein, as well as a method for producing said protein, and to the use of said protein to treat type 1 diabetes.

Abstract: The present invention relates to the use of anti-CD26 antibodies as markers for the screening, diagnosis or monitoring of human subjects having, or suspected to have an autoimmune and/or inflammatory disease, such as rheumatoid arthritis, in particular those in an early stage of the disease. More specifically, it refers to an invitromethod for the screening of a subject having, or suspected of having an autoimmune and/or inflammatory disease, such as rheumatoid arthritis, comprising the following steps: a) determining the levels of anti-CD26 IgG antibodies in an antibody-containing sample isolated from said subject; b) comparing the levels in said antibody-containing sample with a reference value; wherein an increase of the anti-CD26 IgG antibody levels in the subject sample with regard to said reference value is indicative of disease; and wherein said reference value corresponds to the anti-CD26 IgG antibody mean levels in healthy subjects.

Abstract: The present disclosure provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of type 1 diabetes mellitus (T1DM). Such isolated molecules can include a T cell receptor (TCR) having specific binding affinity for a peptide-MHC complex wherein the MHC is an HLA Class I molecule and the peptide is a preproinsulin-derived peptide of 8 to 10 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1).

Abstract: The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (T1DM).